KA
ABBV icon

KDT Advisors’s AbbVie ABBV Stock Holding History

KDT Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$373K Buy
1,482
+455
+44% +$97.9K 0.52% 56
2026
Q1 		$223K Sell
1,027
-830
-45% -$184K 0.36% 69
2025
Q4 		$424K Buy
1,857
+40
+2% +$9.11K 0.6% 51
2025
Q3 		$421K Sell
1,817
-1,202
-40% -$245K 0.62% 48
2025
Q2 		$560K Hold
3,019
– – 0.9% 32
2025
Q1 		$633K Hold
3,019
– – 0.93% 35
2024
Q4 		$536K Buy
+3,019
New +$555K 0.79% 41

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

KDT Advisors's ABBV Position: Q2 2026 in Review

KDT Advisors increased its AbbVie (ABBV) stake by 44% in Q2 2026, buying an estimated $97.9K and bringing the position to 1,482 shares worth $373K. The position accounts for 0.52% of the portfolio, ranked #56.

KDT Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $633K in Q1 2025. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • KDT Advisors held 1,482 shares of AbbVie worth $373K as of Q2 2026.
  • KDT Advisors bought 455 AbbVie shares in Q2 2026, an estimated $97.9K.
  • AbbVie made up 0.52% of KDT Advisors's portfolio in Q2 2026, its #56 holding.
  • KDT Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • KDT Advisors's AbbVie position peaked at $633K in Q1 2025.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on KDT Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.